Blau Farmaceutica SA
BOVESPA:BLAU3
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.67
14.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches BRL.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
BLAU3
stock under the Base Case scenario is
hidden
BRL.
Compared to the current market price of 13.01 BRL,
Blau Farmaceutica SA
is
hidden
.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Blau Farmaceutica SA
BLAU3 looks undervalued. But is it really? Some stocks live permanently below intrinsic value; one glance at Historical Valuation reveals if BLAU3 is one of them.
Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Let our AI compare Alpha Spreadâs intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Blau Farmaceutica SA.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Revenue & Expenses Breakdown
Blau Farmaceutica SA
Balance Sheet Decomposition
Blau Farmaceutica SA
| Current Assets | 1.6B |
| Cash & Short-Term Investments | 297.9m |
| Receivables | 649.8m |
| Other Current Assets | 678.2m |
| Non-Current Assets | 1.8B |
| Long-Term Investments | 265.2m |
| PP&E | 932.3m |
| Intangibles | 533.8m |
| Other Non-Current Assets | 113.4m |
| Current Liabilities | 513.4m |
| Accounts Payable | 273m |
| Accrued Liabilities | 73.1m |
| Other Current Liabilities | 167.3m |
| Non-Current Liabilities | 691.1m |
| Long-Term Debt | 431m |
| Other Non-Current Liabilities | 260.1m |
Free Cash Flow Analysis
Blau Farmaceutica SA
| BRL | |
| Free Cash Flow | BRL |
Earnings Waterfall
Blau Farmaceutica SA
|
Revenue
|
1.8B
BRL
|
|
Cost of Revenue
|
-1.1B
BRL
|
|
Gross Profit
|
706.1m
BRL
|
|
Operating Expenses
|
-283.9m
BRL
|
|
Operating Income
|
422.1m
BRL
|
|
Other Expenses
|
-139.5m
BRL
|
|
Net Income
|
282.7m
BRL
|
BLAU3 Profitability Score
Profitability Due Diligence
Blau Farmaceutica SA's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
Blau Farmaceutica SA's profitability score is hidden . The higher the profitability score, the more profitable the company is.
BLAU3 Solvency Score
Solvency Due Diligence
Blau Farmaceutica SA's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
Blau Farmaceutica SA's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BLAU3 Price Targets Summary
Blau Farmaceutica SA
According to Wall Street analysts, the average 1-year price target for
BLAU3
is 16.54 BRL
with a low forecast of 14.95 BRL and a high forecast of 19.95 BRL.
Dividends
Current shareholder yield for
BLAU3 is
hidden
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
BLAU3
stock under the Base Case scenario is
hidden
BRL.
Compared to the current market price of 13.01 BRL,
Blau Farmaceutica SA
is
hidden
.